Similarly, rilotumumab, a humanized monoclonal antibody targeting HGF, was investigated in phase III trials (RILOMET-1 and RILOMET-2) alongside chemotherapy for advanced MET-positive GC/GEJ cancers, but both studies were prematurely terminated due to an observed increase in mortality among participants receiving rilotumumab [113,114]. This evidence concerns the gene MET and cancer.